| Bioactivity | Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma[1]. |
| In Vivo | Zuberitamab（0.1mg/kg，静脉注射，第0天和第10天，2周）在 IRPα 人化 B-NDG 小鼠肿瘤异种移植模型中，单独使用对肿瘤生长没有影响或影响很小，当与 BR105 联合使用时，可显著抑制肿瘤生长，具有良好的抗肿瘤效果[1]。 |
| Name | Zuberitamab |
| CAS | 2251143-19-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhen-Hua Wu, et al. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint. J Immunother Cancer. 2022 Mar;10(3):e004054. |